Get the Stockscreener App
10.05
2.90%
-0.30
Pre-market:
10.21
0.16
+1.59%
Promis Neurosciences Inc stock is traded at $10.05, with a volume of 6,773.
It is down -2.90% in the last 24 hours and down -3.27% over the past month.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
See More
Previous Close:
$10.35
Open:
$10.51
24h Volume:
6,773
Relative Volume:
0.20
Market Cap:
$90.13M
Revenue:
-
Net Income/Loss:
$-40.62M
P/E Ratio:
-0.5178
EPS:
-19.4076
Net Cash Flow:
$-35.63M
1W Performance:
+3.50%
1M Performance:
-3.27%
6M Performance:
+8.77%
1Y Performance:
-22.62%
1-Day Range:
$10.00
$10.54
1-Week Range:
$9.0901
$10.75
52-Week Range:
$6.27
$39.75
Promis Neurosciences Inc Stock (PMN) Company Profile
Name
Promis Neurosciences Inc
Sector
Industry
Phone
416-847-6898
Address
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
10.05 | 90.13M | 0 | -40.62M | -35.63M | -19.41 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Promis Neurosciences Inc Stock (PMN) Latest News
ProMIS Neurosciences (PMN) Dips 3.54% as Biotech Stock Tests Key Support ZonePrice Action Signals - newsline.com
All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy - Yahoo Finance
Wall Street Analysts Think Promis Neurosciences (PMN) Could Surge 231.78%: Read This Before Placing a Bet - Yahoo Finance
ProMIS Neurosciences Inc. (PMN) Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline Amid Pipeline AdvancesAnalyst Drop Coverage - newsline.com
H.C. Wainwright reiterates Buy on ProMIS Neurosciences stock By Investing.com - Investing.com Canada
PMN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18 - GuruFocus
H.C. Wainwright Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $18 - Moomoo
PMN Q1 2026 Earnings: Narrower-than-Expected Loss Amid Ongoing Clinical DevelopmentROA Comparison - newsline.com
ProMIS Neurosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
PMN Q1 2026 Earnings: EPS Surprises to the Upside Despite Lack of RevenueMargin Guidance - newsline.com
ProMIS Neurosciences (PMN) Slips 3.3% as Biotech Sentiment Shifts – Key Support Holds at $9.56Median Line - newsline.com
ProMIS Neurosciences (PMN) Faces Bearish Pressure as Shares Slide 3.70%Value Stock Ideas - newsline.com
PMN Technical Analysis | Trend, Signals & Chart Patterns | PROMIS NEUROSCIENCES INC (NASDAQ:PMN) - ChartMill
ProMIS Neurosciences to Participate in Upcoming Conferences in June - The Manila Times
Alzheimer’s drug trial data from ProMIS expected in early Q3 2026 - Stock Titan
ProMIS Neurosciences (PMN) Gains Momentum as Shares Test Key Resistance Near $11.29Moving Average Crossovers - newsline.com
ProMIS Neurosciences (PMN) Slips 5.65% as Shares Test Key Support LevelWave Alternation - newsline.com
PMN Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Neurodegenerative PipelineRevenue Breakdown Analysis - The Legal Advocate
PMN Q1 2026 Earnings: Narrower-than-expected Loss; Stock Gains on Pipeline ProgressPretax Income Report - Newser
Yu Fan's ProMIS Neurosciences Inc(PMN) Holding History - GuruFocus
ProMIS Neurosciences (PMN) director granted 16,500 options at $10.77 strike price - Stock Titan
ProMIS Neurosciences (PMN) director granted options on 16,500 shares - Stock Titan
ProMIS Neurosciences (PMN) CEO awarded 160,000 options at $10.77 strike - Stock Titan
ProMIS Neurosciences (PMN) director awarded long-dated stock options - Stock Titan
ProMIS Neurosciences (PMN) awards CSO 50,000 options vesting over 4 years - Stock Titan
Executive at ProMIS (PMN) receives 18,167 stock options expiring 2036 - Stock Titan
ProMIS Neurosciences (PMN) director receives 16,500 stock options grant - Stock Titan
ProMIS Neurosciences (PMN) CDO awarded 50,000 stock options - Stock Titan
Director at ProMIS Neurosciences (PMN) receives new option grants as board compensation - Stock Titan
PMN Q1 2026 Earnings: Narrowed EPS Surprise Drives Positive Stock ReactionDividend Earnings Report - The Legal Advocate
ProMIS Neurosciences (NASDAQ: PMN) shareholders approve larger 2025 stock option plan - Stock Titan
Analysts’ Top Healthcare Picks: ProMIS Neurosciences (PMN), Evolent Health (EVH) - The Globe and Mail
Great Point, Dr. Jay and Nordahl report 9.99% stake in PROMIS (PMN) - Stock Titan
Wellington Group discloses 895,871-share holding in ProMIS (PMN) - Stock Titan
ProMIS Neurosciences Inc. Q1 2026 Financial Results, Forward-Looking Statements, and Risk Factors Overview - Minichart
TradingKey - TradingKey
ProMIS Neurosciences Releases Q1 2026 Financial Results - AlphaStreet
ProMIS Neurosciences Reports Q1 2026 Results, Advances Alzheimer’s PMN310 Trial and Secures $175M Financing - Minichart
ProMIS Neurosciences (PMN) Q1 2026 Earnings: EPS N/A, Revenue N/ - GuruFocus
ProMIS (PMN) Targets Alzheimer's Treatment with Promising Trial and Funding - GuruFocus
ProMIS Neurosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
ProMIS Neurosciences Inc. Q1 2026: Net income $(8.24M), Diluted EPS $(1.26) — 10-Q Summary - TradingView
ProMIS Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] ProMIS Neurosciences Inc. Quarterly Earnings Report - Stock Titan
ProMIS Neurosciences (Nasdaq: PMN) boosts cash with $175M financing and advances PMN310 - Stock Titan
ProMIS Neurosciences Inc. Closes PIPE Financing of Up to $175 Million to Support Alzheimer's Disease Clinical Trial - Quiver Quantitative
Alzheimer's trial fully enrolled as ProMIS funds work through 2027 - Stock Titan
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights - ChartMill
ProMIS Neurosciences (PMN) owners report 181,632 shares (2.0%) in 13G/A amendment - Stock Titan
Insider Purchase: Director at $PMN Buys 4,000 Shares - Moomoo
ProMIS Neurosciences to execute 1-for-25 reverse stock split - MSN
Promis Neurosciences Inc Stock (PMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):